Fig. 4
From: Multiple sclerosis: molecular pathogenesis and therapeutic intervention
Disease-modifying therapies (DMTs) approved for multiple sclerosis. The figure represents the different DMTs according to their clinical efficacy (horizontal axis) and safety concerns (vertical axis). The colors indicate the route of administration: subcutaneous or intramuscular (yellow), oral (orange), or intravenous (red). The dashed borders denote DMTs approved for both relapsing-remitting multiple sclerosis (RRMS) and either secondary progressive MS (SPMS) or primary progressive MS (PPMS). FDA Food and Drug Administration. Created in https://BioRender.com
